Introduction
============

Achalasia is a relatively uncommon disorder of the esophagus affecting the lower esophageal sphincter (LES), resulting in dysphagia [@JR841-1] . Treatment of Achalasia is directed toward decreasing the resting pressure at the LES by: pneumatic dilation (PD) [@JR841-1] , per oral endoscopy myotomy (POEM) [@JR841-2] , or laparoscopic Heller myotomy (LHM) or biochemical reduction in the LES pressure (Botulinum toxin, oral nitrates, etc.). PD is the most effective non-surgical treatment. The short- to medium-term effects are good, nevertheless, up to 66 % of these patients may need reintervention 5 to 10 years later. Moreover, the risk of esophageal perforation (EP) ranges from 1 % to 5 % [@JR841-3] . The question is what can be done if symptoms recur after myotomy and the answer remains unclear. In the pediatric population, after myotomy, performing PD greatly increases the risk of EP. Self-expanding metallic stents (SEMS) are the most common form of palliative treatment for malignant esophageal dysphagia and/or strictures. Today fully-covered SEMS (FC-SEMS) are formally indicated for benign esophageal conditions. Minimal published reports exist about use of SEMS in achalasia in an adults [@JR841-4] .

We report on a 12-year-old boy who presented with recurrent achalasia symptoms after LHM who underwent placement of FC-SEMS.

Case report
===========

A 12-year-old male initially presented with a 12-month history of progressive dysphagia and emesis. On initial diagnosis, upper gastrointestinal series (UGIs) showed a bird's beak with a dilated esophagus proximal to the stenosis. Esophageal manometry and Chagas serology confirmed the diagnosis of achalasia type I (Chicago Classification) not secondary to Chagas. The patient underwent a 4-cm LHM and fundoplication. Concern for dysphagia continued after surgery and persisting stenosis was evidenced by 2 UGIs performed post-surgery and 1 week after the procedure. Four months after myotomy the patient was first seen at our institution. His Eckardt score was 9 (daily dysphagia, regurgitation with each meal, occasional retrosternal pain and \> 10 kg of weight loss). We performed esophageal manometry, which confirmed the diagnosis of achalasia type I. Due to a previous LHM, posterior POEM was considered as an alternative, however, the procedure was not performed in the country by any institution. Moreover, performing PD is associated with a concern about EP and a decision was made to place a stent \[Niti-S Esophageal Covered Stent (Double-type) Taewoong Medical\] 30 mm in diameter and 60 mm long (after approval by the ethics committee of our institution and signing of informed consent by the boy's parents). The patient reported retrosternal discomfort during the first 48 hours, which was treated with oral paracetamol. There were no major adverse events (AEs) post-procedure ( [Fig. 1](#FI841-1){ref-type="fig"} ).
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One month after stent placement, UGIs showed normal gastrointestinal transit. The stent was retrieved 3 months after with esophagogastroduodenoscopy and UGIs showed no distal esophageal stenosis at 6 months ( [Fig. 2](#FI841-2){ref-type="fig"} ). After a follow up of 2 years, the patient reported no dysphagia (Eckardt score \< 3) and had weight gain and growth appropriate for his age.
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Discussion
==========

In patients with achalasia who are low-risk surgical candidates, either a graded PD or LHM with a fundoplication should be performed [@JR841-1] . However, the efficacy of both treatments decreases overtime [@JR841-1] [@JR841-3] .

Multiple studies suggest that in older children, PD is effective and safe as treatment for achalasia [@JR841-5] [@JR841-6] . However, multiple PDs are required. Hamza et al [@JR841-6] , reported a 90 % success rate in children treated with multiple PDs. Adverse events related to PD are: prolonged epigastric pain, esophageal perforation, and aspiration pneumonia [@JR841-5] . In children, surgery is the treatment of choice (open or LHM). However, 7.3 % developed major AEs of esophageal perforation and dysphagia (11.7 %) [@JR841-7] .

Uncovered SEMS are contraindicated for benign pathology because of risk of stent-induced tissue hyperplasia, which will lead to failure of stent removal. However, that risk is eliminated by using a FC-SEMS as long as it is placed for not more than 3 months to avoid risk of stent migration [@JR841-3] .

Cheng et al demonstrated the adequate outcome and safety of large SEMS placed temporarily across the cardia in adults. Recently, the same authors confirmed long-term results obtained with temporary stents and compared the efficacy of different diameters, demonstrating that stents with a 30-mm caliber are more effective after 10-year follow-up [@JR841-8] .

Recently, Cai et al. showed that SEMS was superior to intra-sphincter injection of botulinum toxin for global symptoms, dysphagia scores and basal lower esophageal sphincter pressure and obtained better remission rates after 12 and 36 months of follow-up [@JR841-9] .

It is unknown why a temporary stent should work better than a PD. We speculate that prolonged dilation obtained with a large stent is truly effective because it permanently disrupts the muscular fibers of the LES. The procedure seems to be safe and effective. When compared to PD, the primary benefit is avoidance of perforations. Moreover, fewer procedures are required with lower rates of symptom recurrence [@JR841-10] [@JR841-11] .

Conclusion
==========

Treatment options for achalasia remain palliative. In this setting, where our patient had no initial response to LHM plus the risk of EP with subsequent PD, a FC-SEMS was considered a safe and effective alternative. At 24 months' post-treatment, our patient remains asymptomatic with no dysphagia as evidenced by normal UGIs.

Several technical issues including stent type, diameter, length, removal time and prevention of complications are still open for discussion in children. Large, multicenter, randomized trials are warranted to elucidate the role of FC-SEMS in the treatment of children with achalasia refractory to esophageal myotomy.
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